Prescribing information

 

   

Act directly on the heart with Entresto to improve cardiac function1–3

Entresto, a first-in-class angiotensin receptor-neprilysin inhibitor, has a dual mode of action that simultaneously inhibits vasoconstriction and promotes vasodilation.1

 

 

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

HFrEF, heart failure with reduced ejection fraction.

References

  1. Entresto Summary of Product Characteristics, 2020
  2. Desai AS et al. JAMA 2019; 322(11): 1077–1084.
  3. Januzzi JL Jr et al. JAMA 2019; 322(11): 1085–1095.
ENT20-C046m July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]